BRIEF—Sumitomo Dainippon Phase III DSP-7888 trial in glioblastoma showed low probability of success

Japan’s Sumitomo Dainippon Pharma today announced that the Phase III WIZARD 201G study of investigational cancer vaccine DSP-7888 (adegramotide/nelatimotide) in patients with recurrent or progressive glioblastoma (GBM) will terminate following its second interim analysis after determining there is a low probability of meeting the primary endpoint of overall survival (OS) at the final analysis.

This study evaluated the safety and efficacy of DSP-7888, an investigational WT1 immunotherapeutic cancer vaccine, in combination with bevacizumab versus bevacizumab alone in patients with recurrent or progressive GBM following initial therapy.

Patients were randomized 1:1 in the study with an enrollment planned for 338 patients.

The second interim analysis was done at 185 events for evaluating OS and no new safety concerns were identified by the Independent Data Monitoring Committee (IDMC).

The Phase I/II study of DSP-7888 in combination with checkpoint inhibitors in solid tumors will continue as planned, the company said.